Eli Lilly and Company $LLY Stock Holdings Boosted by GFS Advisors LLC

GFS Advisors LLC lifted its position in shares of Eli Lilly and Company (NYSE:LLY) by 32.1% in the 2nd quarter, Holdings Channel reports. The fund owned 852 shares of the company’s stock after buying an additional 207 shares during the period. GFS Advisors LLC’s holdings in Eli Lilly and Company were worth $664,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of LLY. PNC Financial Services Group Inc. grew its position in shares of Eli Lilly and Company by 97.5% during the first quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company’s stock worth $83,669,349,000 after acquiring an additional 50,002,551 shares during the last quarter. Nuveen LLC bought a new position in Eli Lilly and Company in the 1st quarter valued at about $4,613,912,000. Vanguard Group Inc. grew its position in Eli Lilly and Company by 6.7% in the 1st quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company’s stock valued at $65,432,218,000 after buying an additional 4,975,395 shares in the last quarter. Cohen Investment Advisors LLC grew its position in Eli Lilly and Company by 7,975.5% in the 1st quarter. Cohen Investment Advisors LLC now owns 783,651 shares of the company’s stock valued at $647,225,000 after buying an additional 773,947 shares in the last quarter. Finally, Assenagon Asset Management S.A. grew its position in Eli Lilly and Company by 106.8% in the 2nd quarter. Assenagon Asset Management S.A. now owns 1,481,031 shares of the company’s stock valued at $1,154,508,000 after buying an additional 765,010 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $833.08 on Friday. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $937.00. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The company has a 50-day moving average of $742.42 and a 200-day moving average of $765.94. The firm has a market cap of $788.47 billion, a price-to-earnings ratio of 54.45, a price-to-earnings-growth ratio of 1.16 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. During the same quarter last year, the firm posted $3.92 EPS. The business’s revenue for the quarter was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Insider Activity at Eli Lilly and Company

In other news, Director Gabrielle Sulzberger acquired 117 shares of Eli Lilly and Company stock in a transaction on Tuesday, August 12th. The stock was bought at an average cost of $641.18 per share, with a total value of $75,018.06. Following the completion of the purchase, the director owned 2,703 shares of the company’s stock, valued at $1,733,109.54. This represents a 4.52% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director J Erik Fyrwald acquired 1,565 shares of Eli Lilly and Company stock in a transaction on Tuesday, August 12th. The shares were purchased at an average cost of $642.33 per share, with a total value of $1,005,246.45. Following the completion of the purchase, the director directly owned 74,578 shares of the company’s stock, valued at approximately $47,903,686.74. This represents a 2.14% increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders bought 4,514 shares of company stock valued at $2,894,841. Corporate insiders own 0.13% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. Berenberg Bank reiterated a “hold” rating and issued a $830.00 target price (down previously from $970.00) on shares of Eli Lilly and Company in a research report on Wednesday, September 17th. Leerink Partnrs lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 7th. Cantor Fitzgerald set a $925.00 target price on shares of Eli Lilly and Company and gave the company an “overweight” rating in a research report on Thursday. JPMorgan Chase & Co. decreased their target price on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating for the company in a research report on Tuesday, September 16th. Finally, HSBC raised their price objective on shares of Eli Lilly and Company from $700.00 to $800.00 in a research report on Wednesday, October 1st. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and ten have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and a consensus target price of $948.56.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.